Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 37Carcinoma, Hepatocellular 20Neoplasm Metastasis 19Lung Neoplasms 19Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Stomach Neoplasms 15Colorectal Neoplasms 15Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 10Hodgkin Disease 10Brain Neoplasms 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Colonic Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Basal Cell 6Uveal Melanoma 5Uterine Cervical Neoplasms 5Thyroid Neoplasms 5Sarcoma 5

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1abemaciclib 1Nivolumab 1Injections 1Erlotinib Hydrochloride 1Docetaxel 1Cyclophosphamide 1Cisplatin 1Cetuximab 1Biological Products 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Nivolumab × 90 days × Clear all
NCT03370276 2026-04-02

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
95 enrolled 15 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡